🔴 BioLineRx is trading 5.98% down in after-hours trading after Q2 net loss widened

BioLineRx is trading 5.98% down now at $2.51 after investors continued digesting its August 31, 2026, second-quarter results.

• Revenue was $0.3 million, while net loss widened to $4.3 million; APHEXDA royalty revenue also reflected lower partner sales.
• The company is advancing its early-stage GLIX1 glioblastoma program.
• Pipeline progress has not offset concerns about limited revenue and ongoing losses.